Physician profile
Paul Walker
NPI 1013904358
$17,770.52
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $34.26 · 2021: $139.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $17,021.41 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $147.64 | 2019 | |
| Biom'Up France Sas | $139.40 | 2021 | |
| Merck Sharp & Dohme LLC | $109.11 | 2019 | |
| Pfizer INC. | $59.83 | 2019 | |
| Lilly USA, LLC | $41.58 | 2019 | |
| Emd Serono, INC. | $37.48 | 2019 | |
| Astellas Pharma US INC | $34.24 | 2019-2020 | |
| Gilead Sciences, INC. | $33.32 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $28.94 | 2019 | |
| Amgen INC. | $28.51 | 2019 | |
| Novartis Pharmaceuticals Corporation | $23.26 | 2019 | |
| Kite Pharma, INC. | $15.89 | 2020 | |
| Btg International INC. | $14.81 | 2019 | |
| Genzyme Corporation | $12.73 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $11.44 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $10.93 | 2019 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.